Completion of Facility Enables Initiation of Phase 3 Clinical Trial of Nepafenac in Patients Undergoing Cataract Surgery AUSTIN, Texas, Sept. 12, 2023 /PRNewswire/ — Mati Therapeutics Inc. (“Mati”) announced that it has completed and now occupies a facility dedicated to manufacturing all…